Now Available: Myrtelle ASGCT Symposium Presentation

Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.

Article Date

This article is featured on another website.

Go to article
May 7, 2024

Myrtelle to Host a Symposium on Canavan Disease Clinical Trial Updates and Future Directions for Oligodendrocyte Targeting AAVs at the American Society of Gene and Cell Therapy 27th Annual Meeting in Baltimore on Wednesday, May 8, 2024

Join Myrtelle Inc. at the ASGCT 27th Annual Meeting on May 8, 2024, in Baltimore, for a pivotal symposium on Canavan disease.

May 7, 2024

Myrtelle to Host a Symposium on Canavan Disease Clinical Trial Updates and Future Directions for Oligodendrocyte Targeting AAVs at the American Society of Gene and Cell Therapy 27th Annual Meeting in Baltimore on Wednesday, May 8, 2024

Join Myrtelle Inc. at the ASGCT 27th Annual Meeting on May 8, 2024, in Baltimore, for a pivotal symposium on Canavan disease.

April 24, 2024

Actym Therapeutics Appoints Thomas Smart as CEO

BERKELEY, CA — April 24, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant […]

April 24, 2024

Actym Therapeutics Appoints Thomas Smart as CEO

BERKELEY, CA — April 24, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant […]